Pfizer and Biontech expand study of vaccines for children

The New York Times reports that vaccine studies involving children aged 5-11 will be made more comprehensive in the wake of a request from the FDA.

Photo: Dado Ruvic/REUTERS / X02714

Vaccine trials for children aged 5-11 should be more comprehensive. For this reason, studies of the Pfizer-Biontech vaccine and the Moderna vaccine within this group will now be expanded, writes the New York Times.

The US Food and Drug Administration have called for this to happen, asking vaccine companies to include 3,000 people in the trials, which is twice as many as originally planned, according to the NYT.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs